Trial Profile
Clinical protocol bortezomib consolidation in patients with myeloma following treatment with high-dose melphalan and autologous stem cell support. A randomised NMSG [Nordic Myeloma Study Group] trial (15/05)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 06 May 2011 Results were presented at the 13th International Myeloma Workshop.
- 21 Jun 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 21 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.